These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 2195729)

  • 1. Prognostic factors in stage IV ovarian carcinoma treated with platinum-based regimens.
    Repetto L; Chiara S; Pace M; Guido T; Bruzzone M; Oliva C; Murolo C; Conte PF; Rosso R
    Tumori; 1990 Jun; 76(3):274-7. PubMed ID: 2195729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic overview of chemotherapy effects in ovarian cancer.
    Högberg T; Glimelius B; Nygren P;
    Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclophosphamide-cisplatin versus cyclophosphamide-carboplatin in stage III-IV ovarian carcinoma: a comparison of equally myelosuppressive regimens.
    Edmonson JH; McCormack GM; Wieand HS; Kugler JW; Krook JE; Stanhope CR; Everson LK; Laurie JA; Ebbert LP; Malkasian GD
    J Natl Cancer Inst; 1989 Oct; 81(19):1500-4. PubMed ID: 2674460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Importance of platinum dose intensity in treatment of epithelial ovarian cancer. Austrian Study Group for Therapy of Ovarian Cancer].
    Sevelda P; Kurz C; Obermair A; Vavra N; Breitenecker G; Czerwenka K; Dittrich C; Salzer H
    Wien Klin Wochenschr; 1993; 105(24):732-6. PubMed ID: 8116312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up.
    Akeson M; Zetterqvist BM; Dahllöf K; Brännström M; Horvath G
    Acta Obstet Gynecol Scand; 2008; 87(12):1343-52. PubMed ID: 18951208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-line chemotherapy for carboplatin/paclitaxel-refractory ovarian cancer: are multi-agent chemotherapies of little value truly?
    Ota T; Takeshima N; Takizawa K
    Eur J Gynaecol Oncol; 2011; 32(5):471-5. PubMed ID: 22053655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and toxicity of belotecan with and without cisplatin in patients with recurrent ovarian cancer.
    Nam EJ; Kim JW; Kim JH; Kim S; Kim SW; Jang SY; Lee DW; Jung YW; Kim YT
    Am J Clin Oncol; 2010 Jun; 33(3):233-7. PubMed ID: 19745693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose platinum chemotherapy in advanced ovarian cancer: a phase II study.
    Bertelsen K; Bastholt L
    Gynecol Oncol; 1992 Jan; 44(1):79-82. PubMed ID: 1730430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
    Cicin I; Saip P; Eralp Y; Selam M; Topuz S; Ozluk Y; Aydin Y; Topuz E
    Gynecol Oncol; 2008 Jan; 108(1):136-40. PubMed ID: 17936342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.
    Holloway RW; Mehta RS; Finkler NJ; Li KT; McLaren CE; Parker RJ; Fruehauf JP
    Gynecol Oncol; 2002 Oct; 87(1):8-16. PubMed ID: 12468336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer.
    Shapiro JD; Rothenberg ML; Sarosy GA; Steinberg SM; Adamo DO; Reed E; Ozols RF; Kohn EC
    Cancer; 1998 Nov; 83(9):1980-8. PubMed ID: 9806657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
    Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
    Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group.
    Bonomi PD; Finkelstein DM; Ruckdeschel JC; Blum RH; Green MD; Mason B; Hahn R; Tormey DC; Harris J; Comis R
    J Clin Oncol; 1989 Nov; 7(11):1602-13. PubMed ID: 2553879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group.
    Markman M; Bundy BN; Alberts DS; Fowler JM; Clark-Pearson DL; Carson LF; Wadler S; Sickel J
    J Clin Oncol; 2001 Feb; 19(4):1001-7. PubMed ID: 11181662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin combined with carboplatin: a new way of intensification of platinum dose in the treatment of advanced ovarian cancer. Belgian Study Group for Ovarian Carcinoma.
    Piccart MJ; Nogaret JM; Marcelis L; Longrée H; Ries F; Kains JP; Gobert P; Domange AM; Sculier JP; Gompel C
    J Natl Cancer Inst; 1990 Apr; 82(8):703-7. PubMed ID: 2181152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma.
    Trimbos JB; Parmar M; Vergote I; Guthrie D; Bolis G; Colombo N; Vermorken JB; Torri V; Mangioni C; Pecorelli S; Lissoni A; Swart AM; ;
    J Natl Cancer Inst; 2003 Jan; 95(2):105-12. PubMed ID: 12529343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: a Gynecologic Oncology Group study.
    Hess LM; Barakat R; Tian C; Ozols RF; Alberts DS
    Gynecol Oncol; 2007 Nov; 107(2):260-5. PubMed ID: 17675142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term results and prognostic factors in patients with epithelial ovarian cancer.
    Brun JL; Feyler A; Chêne G; Saurel J; Brun G; Hocké C
    Gynecol Oncol; 2000 Jul; 78(1):21-7. PubMed ID: 10873404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.